Status
Conditions
Treatments
About
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.
Full description
Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging. With the development of artificial intelligence, much more potential lies in the histopathology images of HE slices in primary gliomas could be excavated to aid prediction of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed molecular pathology, histopathology image data and with sufficient sample size for deep learning (>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Zhenyu Zhang, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal